PMWC caught up with Alex Zhavoronkov, CEO of Insilico Medicine, the winner of PMWC’s 2015 Most Promising Company Competition to get an update on the company’s progress and tease out some advice for this year’s Company Showcase Competition contenders.

Alex told us that PMWC Silicon Valley 2015 was a landmark event in the company’s history and allowed their team to believe in themselves because it was a positive first test of investor appetite. Today, Alex looks at Insilico as the “Bell Labs for AI in healthcare” with more than 200 different projects that they are taking to proof of concept and then either licensing out or creating joint ventures around.

Company Update Highlights:

  • Hired the top deep learning talent all over the world through hackathons and then trained them in bioinformatics.
  • Launched several biomarkers developed using a new approach to AI, discovered a range of targets and molecules that are going through validation. Partnered with Life Extension, which launched two Insilico nutraceutical products. Currently capturing the effectiveness of these nutraceuticals using a system called Young.AI, available online. Over 65,000 people worldwide bought the nutraceuticals in first six months since launch.
  • In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies based on potential for social impact.
  • Breakthrough at the end of 2015. Began using a new technique in deep learning first proposed by Ian Goodfellow,called Generative Adversarial Networks (GANs) that allows “imagining” new objects with a specific set of characteristics. Coupled that with “reinforcement learning”, the technique used by Deep Mind to defeat the Go champion, to generate novel molecular structures with a desired set of characteristics.
  • Published the first proofs of concept and quickly became popular in the pharma world.
  • At JP Morgan 2016, met with top biotech investors and pharma executives. Met partners of Jim Mellon, the “British Warren Buffett”, who invested in Insilico and formed a separate company with Greg Bailey, who recently sold Medivation for $14.5 billion, and Declan Doogan, developer of Zoloft, Lipitor and Viagra. This all-star team is now developing molecules for age-related diseases generated entirely using AI.
  • This same team led the most recent round of funding.
  • Expanded into Asia with R&D centers in Taiwan, Republic of China and Hong Kong,as well as a JV in Korea, with a focus on cosmetics applications. Working on expanding into China.
Q: Everyone is talking about the China’s big push into AI. What is happening in China?

 

A: China is the new Silicon Valley and the new frontier in human development. Everyone I know there is working on a startup. There is abundant capital to fuel growth and the large corporations are open to collaboration. Even some of the Big Pharma country heads in China are more innovative and have more freedom to operate than their counterparts in the open innovation departments at headquarters

In China people have a very different attitude toward personal data. For instance, when you buy a SIM card a picture is taken of you with your passport open. This really propels innovation much faster than in other geographies. The availability of large data sets and the freedom to work with the data also ignites innovation there. Tencent, the company that runs WeChat, Alibaba, Baidu, WuXi, BGI, is pushing very hard into AI with all the companies.  And if AI is the new combustion engine and the data is the new electricity, China is the new epicenter of a data-driven economy.

However, the problem they will be facing soon is population specificity with some of the biomarkers and biological targets. When you use only Chinese data to build your predictors, classifiers and generators the systems will be very biased and may not work in European and other populations.

One of the technologies that will help Chinese companies as well as the rest of the world access human health data in a very ethical and secure way is blockchain. And it turns out that some of our projects in AI can help with that.

I am very happy to see that Chinese AI companies are among the participants of PMWC Silicon Valley 2018 and we are very much looking forward to establishing fruitful collaborations.

Q: To be the leader in AI you need a lot of data. You mentioned blockchain as one of the potential enablers of secure and efficient data acquisition. Can you elaborate?

 

A: Blockchain is a distributed ledger technology which can be used to enable individuals to take control of their life data. Currently there is a disconnect between individuals, medical institutions, laboratories, pharmaceutical companies and regulators. This disconnect is resulting in unnecessary regulatory barriers. Also individuals often don’t know what data they have, how useful it is and they don’t have the ability to sell or license their data to companies.

Our AI can show them how valuable their various types of data is– individually and in combination and in time. We published a seminar paper on this subject. We also partnered with one of the largest companies in blockchain technology called BitFury Group, which helps put entire governments on blockchain to develop the “Internet of human life data”. We formed a subsidiary called Longenesis, Limited, to unlock the value of multi-omics data and allow companies and researchers to gain access to the vast amounts of data from various population groups internationally.

We are also planning to introduce a new crypto token called LifePound which will allow people to profit from their data in more ways than was previously imaginable. In theory, governments be will able to introduce a universal basic income to people who regularly provide their life data for research purposes while encouraging them to pursue healthy lifestyles.

Longenesis may be one of the highest-impact projects in our portfolio. We already have the working prototype running on BitFury’s Exonum blockchaiin platform and data verification, quality control, trust rating and authentication system. It uses our deep learning systems and a small team is in Hong Kong working on the Longenesis “Life on Blockchain” pilot. We are presenting this system at conferences throughout Africa such as in Nigeria, South Africa, and Botswana to ensure that they are the early adopters when we launch. Africa may become the next “Saudi Arabia” of data and we may be able to improve millions of lives by empowering the people to take control of their life data, their health while gaining access to the most disruptive technologies: AI, blockchain and longevity biotechnology.

Q: At PMWC 2015 you were focused on aging research. Did your focus shift?

A: Absolutely not. Our bet on aging research really paid off. We treat aging as a disease that every living creature has and chronological age as the stage of this disease. When you train the deep neural networks to predict age using different data types: Pictures, blood tests, tissue-specific transcriptomes, proteomes, imaging data, microbiome, voice, videos, wearable data and even data from the electronic nose (a device that identifies the specific components of an odor and analyzes its chemical makeup to identify it), the Deep Neural Networks capture the most biologically-relevant features and you can integrate multi-omics data. You can later extract the most important features and use them as targets, or re-train the DNNs on the various diseases, when only a limited number of samples are available. We understand that a person today is different from the same person tomorrow. Essentially we are our age. During aging we change at every level. We now realize that age is probably the most important and universal feature every living being has. I already explained why age is important for training the Deep Neural Networks to predict age on multi-modal data and to developing biomarkers, and to understanding the population specificity of biomarkers, for example. When people think about personalized medicine, they think about the differences between people. But when you think about the same person at a different age as a different person, you get much more value from the data and understand the value of the various data types. A very simple example of this is cancer immune therapy. The person may respond very well to checkpoint inhibitors in his 50s and 60s, but may not respond to the same therapy in his 70s and 80s, due to immune senescence and changes in many other systems.

Even the blockchain projects at Insilico utilize aging research for life data quality control, authentication, and verification as well as for reconstruction of incomplete data sets. Age is the most important feature for us and we want to track it at every level. We regularly run hackathons at AgeNet.Net and other resources to build the predictors of both chronological and biological age using any data type. We also helped conceive MouseAge.org to do the same in mice and hopefully, in other animals. We want to see aging, feel aging, smell aging and build a virtual model of aging to be able to understand the effects of aging on disease.

Q: What are your long-term plans as a company, say 10 years out?

A: Our very long term plan is to achieve excellence in AI for longevity and to refocus from treatment to prevention. Think aging without losing. Ultimately we would like to make humans more resistant to age-associated changes and to changes in the environment. Making humans more age-resistant, radiation-resistant and infectious disease-resistant is the long term goal of the company.

Q: Do you have any advice for the 2018 PMWC contenders?

A: The jury is comprised of professional VCs. VCs like to hear about the technology, the business model, and the team as well as the go-to-market strategy. So it is really a straight forward VC pitch. PMWC Silicon Valley 2018 will be the highlight of a very transformative year in human history. And it looks like everyone in AI for healthcare will be there. If you’re interested in AI, you should be there and invite your friends to attend.

Interview with Gabriel Bien-Willner of Palmetto GBA

Q: What does your role entail as the director of the MolDX program at Palmetto GBA?

A: The job directing MolDX is multifaceted; first and foremost the MolDX program is responsible for assessing molecular diagnostic tests on the market and makes coverage and pricing determinations for such tests and technology. This is usually done through local coverage determination policies or technical assessments.

Read More

Interview with Peter Marks of FDA

Q: The CBER’s Regenerative Medicine Advanced Therapy Designation program has been very successful, with about 100 requests for designation in the two years of its existence. Can you please tell us about the program and how it was put together?

A: The Regenerative Medicine Advanced Therapy (RMAT) Designation program came into being as part of the 21st Century Cures Act that was signed into law on December 13, 2016.

Read More

Interview with Calum MacRae of Harvard Medical School

Q: What patient data do we need to better understand the underlying cause of disease and how to prevent it?

A: Medicine at present is highly underdetermined and data poor. To be precise, one must be comprehensive, so medicine (with our consent) will use not only what we currently conceive of as biomedical information, but also data from across our lives.

Read More

Headlines from PMWC 2019 Silicon Valley

A big ‘Thank You’ to all of our presenters and attendees for celebrating 10 years of precision medicine progress with us! PMWC 2019 Silicon Valley was attended by 2000 participants from 35 countries, which included over 400 speakers in 5 parallel tracks!

Read More

Interview with Ken Bloom of Ambry Genetics

Q: Tell us more about your organization/company. What patient population are you serving and which services are you specializing in?

A: Ambry Genetics is a recognized leader in high quality complex genetic testing. We seek to find the genomic cause or contributors to rare diseases, abnormal phenotypes and hereditary disorders.

Read More

Interview with Lee Pierce of Sirius Computer Solutions

Q: What is the state of big data and analytics in healthcare, and how to best use the reams of data available?

A: More than ever, Healthcare organizations are achieving measurable value through use of their data and analytics assets. There is more raw material available than ever to create value. This raw material is the data flowing from internal systems and applications and also from devices and systems external to healthcare organizations.

Read More

Interview with Anita Nelsen of PAREXEL

Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we expect these new technologies being part of routine clinical care?

A: Today’s emerging technologies are making the promise of individualized treatment a reality.

Read More

Interview with Ilan Kirsch of Adaptive Biotechnologies

Q: The Nobel Prize in Medicine was awarded recently to James Allison and Tasuku Honjo for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. The Nobel committee hailed their accomplishments as establishing “an entirely new principle for cancer therapy.” What is your first-hand experience the impact that those new drugs had on patients?

A: For decades cancer was viewed as solely a cell-autonomous condition.

Read More

BMS buys Celgene | Lilly buys Loxo Oncology – Does this Signal a Return to Strong Deal-Making Activities in 2019?

Bristol-Myers Squibb’s blockbuster $74B deal to buy Celgene creates an oncology powerhouse amid industrywide excitement about the rapidly evolving science and explosive growth of the sector. The agreement could signal a return to deal-making for the pharmaceutical industry in the $133B global oncology therapeutics market.

Read More

Interview with Gini Deshpande of NuMedii

Q: What need is NuMedii addressing?

A: NuMedii, has been pioneering the use of Big Data, artificial intelligence (AI) and systems biology since 2010 to accelerate the discovery of precision therapies to address high unmet medical needs. Artificial Intelligence approaches are a natural fit to harness Big Data as they provide a framework to ‘train’ computers to recognize patterns and sift through vast amounts of new and existing genomic

Read More

Interview with Minnie Sarwal of UCSF

Q: Genomic medicine is entering more hospitals and bringing with it non-invasive technology that can be used to better target and treat diseases. What are some key milestones that contributed to this trend?

A: Completion of complete sequence data from the human genome project, and the advances in proteomic, microRNA and epigenetic assays added a layer of pathway biology to the understanding of human diseases.

Read More

Interview with Shidong Jia of Predicine

Q: Once sequencing has been validated as a clinical solution via trusted workflows, and coinciding with the technological developments driving costs lower, we can expect accelerated human genome profiling for clinical Dx. How soon, do you think, will we see accelerated growth and what can we expect?

A: We will see accelerated human genome profiling for clinical Dx in 2019 and the coming years as more biomarker-based cancer drugs are gaining approval.

Read More

Interview with Iya Khalil of GNS Healthcare

Q: Artificial intelligence (AI) techniques have sent vast waves across healthcare, even fueling an active discussion of whether AI doctors will eventually replace human physicians in the future. Do you believe that human physicians will be replaced by machines in the foreseeable future? What are your thoughts?

A: I think that there’s a lot of speculation and uncertainty around AI, but I don’t foresee a time when we won’t need physicians.

Read More

Interview with Ilya Michael Rachman of Immix Biopharma Inc.

Q: The Nobel Price in Medicine was awarded recently to James Allison and Tasuku for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. The Nobel committee hailed their accomplishments as establishing “an entirely new principle for cancer therapy.” Besides CAR T-cell therapy what do you think next generation immunotherapies will look like to successfully combat cancer?

A: The next generation of immunotherapies will build on the insights discovered by immunologists like James Allison and Tasuku Honjo and extend them to modify the body’s response to tumors.

Read More

Join me to Kick off PMWC Silicon Valley in the Santa Clara Convention Center, Focusing on Every Element of Precision Medicine

My team worked in collaboration with Bill Dalton, Kim Blackwell, Atul Butte / India Hook Barnard, Nancy Davidson and Sharon Terry to create a program that touches every component of precision medicine while bringing together all of its key stakeholders. Leading participating institutions including Stanford Health Care, UCSF, Duke Health, Duke University, John Hopkins University, University of Michigan and more will share their learnings and experiences and their successes and challenges, as they make precision medicine the new standard of care for all.

Read More
Johns Hopkins
University Of Michigan

The Precision Medicine World Conference (PMWC), in its 17th installment, will take place in the Santa Clara Convention Center (Silicon Valley) on January 21-24, 2020. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

See 2019 Agenda highlights:

  • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • AI & Data Science Showcase
    • Clinical & Research Tools Showcase
    • Clinical Dx Showcase
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Digital Health/Health and Wellness
    • Digital Phenotyping
    • Diversity in Precision Medicine
    • Drug Development (PPPs)
    • Early Days of Life Sequencing
    • Emerging Technologies in PM
    • Emerging Therapeutic Showcase
    • FDA Efforts to Accelerate PM
    • Gene Editing
    • Genomic Profiling Showcase
    • Immunotherapy Sessions & Showcase
    • Implementation into Health Care Delivery
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Microbial Profiling Showcase
    • Microbiome
    • Neoantigens
    • Next-Gen. Workforce of PM
    • Non-Clinical Services Showcase
    • Pharmacogenomics
    • Point-of Care Dx Platform
    • Precision Public Health
    • Rare Disease Diagnosis
    • Resilience
    • Robust Clinical Decision Support Tools
    • Wellness and Aging Showcase

See 2019 Agenda highlights:

    • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • AI & Data Science Showcase
      • Clinical & Research Tools Showcase
      • Clinical Dx Showcase
      • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
      • Digital Health/Health and Wellness
      • Digital Phenotyping
      • Diversity in Precision Medicine
      • Drug Development (PPPs)
      • Early Days of Life Sequencing
      • Emerging Technologies in PM
      • Emerging Therapeutic Showcase
      • FDA Efforts to Accelerate PM
      • Gene Editing / CRISPR
      • Genomic Profiling Showcase
      • Immunotherapy Sessions & Showcase
      • Implementation into Health Care Delivery
      • Large Scale Bio-data Resources to Support Drug Development (PPPs)
      • Microbial Profiling Showcase
      • Microbiome
      • Neoantigens
      • Next-Gen. Workforce of PM
      • Non-Clinical Services Showcase
      • Pharmacogenomics
      • Point-of Care Dx Platform
      • Precision Public Health
      • Rare Disease Diagnosis
      • Resilience
      • Robust Clinical Decision Support Tools
      • Wellness and Aging Showcase
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 2000+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
Get Updates
Sign up for occasional updates on upcoming conferences, news, and other information.
We respect your privacy and will never share your email with anyone.
Something went wrong, please verify your input.
Thank you for signing up!

Get Exclusive Access to the Top PMWC Talks

To receive the most comprehensive news and updates from the field of precision medicine, subscribe to the newsletter here.

Bonus for suscribing, you will get the access code for the top 3 talk videos from January's Precision Medicine World Conference.

You have successfully subscribed, you can access the talks here.